NMN协生菌:对阿尔茨海默氏病的多面治疗方法
Caifeng Li1, Xiaodong Zhao1, Huilian Xu1
1College of Biological Science and Technology, University of Jinan, Jinan, 250022, China.
Neurochemical research
|July 22, 2024
概括
尼古丁胺胺单核酸 (NMN) 协生菌在通过减少粉样β斑块和神经炎症来对抗阿尔茨海默病 (AD) 方面表现有前途. 这种干预也改善了肠道健康,增强了肠道屏障功能,为AD提供了多方面的治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 胃肠病学 胃肠病学
- 老年学是一门学科.
- 药理学 药理学是指药理学的学科.
背景情况:
- 由于人口老龄化,阿尔茨海默病 (AD) 构成了日益严重的全球健康挑战.
- 迫切需要新的治疗策略来解决AD的复杂病理.
- 人们越来越认识到肠-大脑轴在AD等神经退行性疾病中的作用.
研究的目的:
- 在阿尔茨海默氏症小鼠模型中研究尼古丁胺胺单核酸 (NMN) 协生菌的治疗潜力.
- 评估NMN协生菌对关键AD病理学的影响,包括粉样β沉积和神经炎症.
- 评估NMN协生菌对肠道健康和屏障完整性的影响.
主要方法:
- 在APP/PS1转基因小鼠中,使用NMN协生菌 (NMN,Lactiplantibacillus plantarum CGMCC 1.16089和乳糖).
- 在大脑 (大脑皮层和海马体) 中评估了粉样蛋白-β (Aβ) 沉积.
- 评估了肠道组织病理学,紧结蛋白表达 (Claudin-1,ZO-1),炎症性细胞因子水平 (IL-1β,IL-6,TNF-α) 和反应性氧物种 (ROS) 水平.
主要成果:
- NMN协生菌显著减少了Aβ沉积在大脑中的67% (皮质) 和60% (海马).
- 通过改善组织病理变化,恢复杯状细胞数量和调高紧密结合蛋白来改善肠道健康,从而增强肠道屏障完整性.
- 通过减少促炎性细胞因子减少神经炎症,通过降低ROS水平减轻氧化应激,从而减少神经炎症.
结论:
- 通过准多种病理途径,NMN协生菌对阿尔茨海默病具有显著的治疗潜力.
- 这种干预措施增强了肠道屏障功能,减少了神经炎症和氧化应激,有助于减少Aβ沉积.
- 对机制的进一步研究,例如NLRP3炎症酶通路,可能会揭示AD的新型治疗点.
更多相关视频
10:08Microtransplantation of Synaptic Membranes to Reactivate Human Synaptic Receptors for Functional Studies
Published on: July 20, 2022
2.2K
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
9.3K
相关概念视频
01:22Alzheimer's Disease: Treatment
172
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
172
01:26Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
114
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
114